Disc Medicine (IRON) Projected to Announce Quarterly Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.63) per share and revenue of $1.88 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $81.16 on Wednesday. The firm has a market cap of $3.12 billion, a P/E ratio of -12.33 and a beta of 0.96. The firm’s 50-day simple moving average is $71.35 and its 200-day simple moving average is $70.81. Disc Medicine has a twelve month low of $40.00 and a twelve month high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14.

Insider Activity at Disc Medicine

In other Disc Medicine news, Director Kevin Bitterman sold 25,519 shares of the business’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $80.23, for a total value of $2,047,389.37. Following the transaction, the director owned 12,991 shares of the company’s stock, valued at approximately $1,042,267.93. The trade was a 66.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John D. Quisel sold 33,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the sale, the chief executive officer owned 226,064 shares in the company, valued at $17,892,965.60. The trade was a 12.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 173,046 shares of company stock valued at $13,591,034 in the last three months. Corporate insiders own 3.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on IRON shares. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Thursday, October 15th. Cantor Fitzgerald upped their price objective on Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a research note on Monday, October 19th. Truist Financial increased their target price on Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Jefferies Financial Group restated a “buy” rating and set a $149.00 target price on shares of Disc Medicine in a research report on Wednesday, October 21st. Finally, BMO Capital Markets raised their target price on Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a research report on Monday, October 19th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $122.70.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.